25 XP   0   0   10

Enorama Pharma AB
Buy, Hold or Sell?

Let's analyse Enorama together

PenkeI guess you are interested in Enorama Pharma AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Enorama Pharma AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Enorama Pharma AB

I send you an email if I find something interesting about Enorama Pharma AB.

Quick analysis of Enorama (30 sec.)










What can you expect buying and holding a share of Enorama? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.34
Expected worth in 1 year
kr0.13
How sure are you?
36.4%

+ What do you gain per year?

Total Gains per Share
kr-0.21
Return On Investment
-9.1%

For what price can you sell your share?

Current Price per Share
kr2.30
Expected price per share
kr2 - kr10.30
How sure are you?
50%

1. Valuation of Enorama (5 min.)




Live pricePrice per Share (EOD)

kr2.30

Intrinsic Value Per Share

kr-5.72 - kr-6.66

Total Value Per Share

kr-5.38 - kr-6.31

2. Growth of Enorama (5 min.)




Is Enorama growing?

Current yearPrevious yearGrowGrow %
How rich?$1.7m$732.6k$957k56.6%

How much money is Enorama making?

Current yearPrevious yearGrowGrow %
Making money-$1m-$984k-$47.6k-4.6%
Net Profit Margin-9,174.1%-15,751.2%--

How much money comes from the company's main activities?

3. Financial Health of Enorama (5 min.)




What can you expect buying and holding a share of Enorama? (5 min.)

Welcome investor! Enorama's management wants to use your money to grow the business. In return you get a share of Enorama.

What can you expect buying and holding a share of Enorama?

First you should know what it really means to hold a share of Enorama. And how you can make/lose money.

Speculation

The Price per Share of Enorama is kr2.3. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Enorama.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Enorama, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.34. Based on the TTM, the Book Value Change Per Share is kr-0.05 per quarter. Based on the YOY, the Book Value Change Per Share is kr0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Enorama.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.02-1.0%-0.02-0.8%-0.02-0.7%-0.01-0.5%-0.01-0.4%
Usd Book Value Change Per Share0.000.0%0.00-0.2%0.010.4%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.00-0.2%0.010.4%0.000.0%0.000.0%
Usd Price Per Share0.35-0.46-1.38-2.89-3.41-
Price to Earnings Ratio-3.98--6.84--21.41--85.68--135.39-
Price-to-Total Gains Ratio-1,432.01--365.04--461.06--760.26--330.82-
Price to Book Ratio11.21-16.03--322.00-582.24-719.36-
Price-to-Total Gains Ratio-1,432.01--365.04--461.06--760.26--330.82-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.21137
Number of shares4731
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (4731 shares)-22.810.96
Gains per Year (4731 shares)-91.253.84
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-91-10104-6
20-182-19208-2
30-274-2830122
40-365-3740156
50-456-46501910
60-547-55602314
70-639-64702718
80-730-73803122
90-821-82903526
100-912-92003830

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.032.00.03.0%1.032.00.03.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%12.021.00.036.4%12.021.00.036.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.033.00.0%0.00.033.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%12.021.00.036.4%12.021.00.036.4%

Fundamentals of Enorama

About Enorama Pharma AB

Enorama Pharma AB (publ), a pharmaceutical company, produces and supplies medical chewing gum and other nicotine products. It also offers nicotine pouches and medical cannabis products. Enorama Pharma AB (publ) was incorporated in 2006 and is based in Malmö, Sweden.

Fundamental data was last updated by Penke on 2024-04-21 10:28:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Enorama Pharma AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Enorama earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Enorama to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -7,993.0% means that kr-79.93 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Enorama Pharma AB:

  • The MRQ is -7,993.0%. The company is making a huge loss. -2
  • The TTM is -9,174.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-7,993.0%TTM-9,174.1%+1,181.1%
TTM-9,174.1%YOY-15,751.2%+6,577.1%
TTM-9,174.1%5Y-5,392.5%-3,781.7%
5Y-5,392.5%10Y-3,316.3%-2,076.1%
1.1.2. Return on Assets

Shows how efficient Enorama is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Enorama to the Drug Manufacturers - Specialty & Generic industry mean.
  • -40.0% Return on Assets means that Enorama generated kr-0.40 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Enorama Pharma AB:

  • The MRQ is -40.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -31.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-40.0%TTM-31.8%-8.2%
TTM-31.8%YOY-22.8%-9.0%
TTM-31.8%5Y-20.6%-11.2%
5Y-20.6%10Y-18.5%-2.1%
1.1.3. Return on Equity

Shows how efficient Enorama is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Enorama to the Drug Manufacturers - Specialty & Generic industry mean.
  • -70.4% Return on Equity means Enorama generated kr-0.70 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Enorama Pharma AB:

  • The MRQ is -70.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -61.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-70.4%TTM-61.4%-8.9%
TTM-61.4%YOY-36.5%-24.9%
TTM-61.4%5Y-153.0%+91.6%
5Y-153.0%10Y-118.2%-34.8%

1.2. Operating Efficiency of Enorama Pharma AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Enorama is operating .

  • Measures how much profit Enorama makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Enorama to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -6,536.6% means the company generated kr-65.37  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Enorama Pharma AB:

  • The MRQ is -6,536.6%. The company is operating very inefficient. -2
  • The TTM is -8,533.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-6,536.6%TTM-8,533.4%+1,996.8%
TTM-8,533.4%YOY-16,124.7%+7,591.3%
TTM-8,533.4%5Y-5,328.3%-3,205.1%
5Y-5,328.3%10Y-3,245.8%-2,082.5%
1.2.2. Operating Ratio

Measures how efficient Enorama is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 66.37 means that the operating costs are kr66.37 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Enorama Pharma AB:

  • The MRQ is 66.366. The company is inefficient in keeping operating costs low. -1
  • The TTM is 87.023. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ66.366TTM87.023-20.657
TTM87.023YOY166.114-79.091
TTM87.0235Y55.195+31.828
5Y55.19510Y34.048+21.147

1.3. Liquidity of Enorama Pharma AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Enorama is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.27 means the company has kr1.27 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Enorama Pharma AB:

  • The MRQ is 1.269. The company is just able to pay all its short-term debts.
  • The TTM is 1.076. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.269TTM1.076+0.192
TTM1.076YOY0.786+0.290
TTM1.0765Y0.933+0.144
5Y0.93310Y1.067-0.134
1.3.2. Quick Ratio

Measures if Enorama is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Enorama to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.85 means the company can pay off kr0.85 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Enorama Pharma AB:

  • The MRQ is 0.849. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.668. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.849TTM0.668+0.181
TTM0.668YOY0.543+0.125
TTM0.6685Y0.660+0.008
5Y0.66010Y0.839-0.179

1.4. Solvency of Enorama Pharma AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Enorama assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Enorama to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.43 means that Enorama assets are financed with 43.2% credit (debt) and the remaining percentage (100% - 43.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Enorama Pharma AB:

  • The MRQ is 0.432. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.480. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.432TTM0.480-0.049
TTM0.480YOY0.836-0.356
TTM0.4805Y0.757-0.277
5Y0.75710Y0.679+0.078
1.4.2. Debt to Equity Ratio

Measures if Enorama is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Enorama to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 76.0% means that company has kr0.76 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Enorama Pharma AB:

  • The MRQ is 0.760. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.985. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.760TTM0.985-0.225
TTM0.985YOY0.927+0.059
TTM0.9855Y9.601-8.616
5Y9.60110Y7.118+2.483

2. Market Valuation of Enorama Pharma AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Enorama generates.

  • Above 15 is considered overpriced but always compare Enorama to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -3.98 means the investor is paying kr-3.98 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Enorama Pharma AB:

  • The EOD is -2.389. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.984. Based on the earnings, the company is expensive. -2
  • The TTM is -6.839. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.389MRQ-3.984+1.596
MRQ-3.984TTM-6.839+2.855
TTM-6.839YOY-21.407+14.568
TTM-6.8395Y-85.677+78.837
5Y-85.67710Y-135.387+49.711
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Enorama Pharma AB:

  • The EOD is -2.319. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.869. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -15.175. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.319MRQ-3.869+1.549
MRQ-3.869TTM-15.175+11.306
TTM-15.175YOY-32.369+17.194
TTM-15.1755Y-87.293+72.118
5Y-87.29310Y-128.799+41.506
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Enorama is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 11.21 means the investor is paying kr11.21 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Enorama Pharma AB:

  • The EOD is 6.723. Based on the equity, the company is overpriced. -1
  • The MRQ is 11.214. Based on the equity, the company is expensive. -2
  • The TTM is 16.026. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD6.723MRQ11.214-4.491
MRQ11.214TTM16.026-4.812
TTM16.026YOY-321.999+338.024
TTM16.0265Y582.242-566.217
5Y582.24210Y719.358-137.116
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Enorama Pharma AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.003-0.052+1858%0.088-103%0.002-221%0.010-126%
Book Value Per Share--0.3420.322+6%0.140+145%0.152+125%0.140+144%
Current Ratio--1.2691.076+18%0.786+61%0.933+36%1.067+19%
Debt To Asset Ratio--0.4320.480-10%0.836-48%0.757-43%0.679-36%
Debt To Equity Ratio--0.7600.985-23%0.927-18%9.601-92%7.118-89%
Dividend Per Share----0%-0%-0%-0%
Eps---0.241-0.195-19%-0.177-27%-0.137-43%-0.101-58%
Free Cash Flow Per Share---0.248-0.171-31%-0.145-41%-0.130-47%-0.101-59%
Free Cash Flow To Equity Per Share---0.0520.002-2423%-0.034-34%-0.009-83%0.003-1671%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---6.655--------
Intrinsic Value_10Y_min---5.718--------
Intrinsic Value_1Y_max---0.553--------
Intrinsic Value_1Y_min---0.543--------
Intrinsic Value_3Y_max---1.749--------
Intrinsic Value_3Y_min---1.668--------
Intrinsic Value_5Y_max---3.049--------
Intrinsic Value_5Y_min---2.822--------
Market Cap131356450.000-67%219096847.450286237126.850-23%860474698.113-75%1862562864.345-88%2160463019.944-90%
Net Profit Margin---79.930-91.741+15%-157.512+97%-53.925-33%-33.163-59%
Operating Margin---65.366-85.334+31%-161.247+147%-53.283-18%-32.458-50%
Operating Ratio--66.36687.023-24%166.114-60%55.195+20%34.048+95%
Pb Ratio6.723-67%11.21416.026-30%-321.999+2971%582.242-98%719.358-98%
Pe Ratio-2.389+40%-3.984-6.839+72%-21.407+437%-85.677+2050%-135.387+3298%
Price Per Share2.300-67%3.8365.012-23%15.067-75%31.395-88%37.091-90%
Price To Free Cash Flow Ratio-2.319+40%-3.869-15.175+292%-32.369+737%-87.293+2156%-128.799+3229%
Price To Total Gains Ratio-858.539+40%-1432.006-365.037-75%-461.057-68%-760.264-47%-330.822-77%
Quick Ratio--0.8490.668+27%0.543+56%0.660+29%0.839+1%
Return On Assets---0.400-0.318-21%-0.228-43%-0.206-49%-0.185-54%
Return On Equity---0.704-0.614-13%-0.365-48%-1.530+117%-1.182+68%
Total Gains Per Share---0.003-0.052+1858%0.088-103%0.002-221%0.010-126%
Usd Book Value--1795542.2001689719.350+6%732626.800+145%844559.383+113%764787.598+135%
Usd Book Value Change Per Share--0.000-0.005+1858%0.008-103%0.000-221%0.001-126%
Usd Book Value Per Share--0.0310.030+6%0.013+145%0.014+125%0.013+144%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.022-0.018-19%-0.016-27%-0.013-43%-0.009-58%
Usd Free Cash Flow---1301120.200-899448.275-31%-763091.650-41%-705909.568-46%-545538.061-58%
Usd Free Cash Flow Per Share---0.023-0.016-31%-0.013-41%-0.012-47%-0.009-59%
Usd Free Cash Flow To Equity Per Share---0.0050.000-2423%-0.003-34%-0.001-83%0.000-1671%
Usd Market Cap12071657.755-67%20135000.28126305191.958-23%79077624.757-75%171169527.233-88%198546551.533-90%
Usd Price Per Share0.211-67%0.3530.461-23%1.385-75%2.885-88%3.409-90%
Usd Profit---1263441.200-1031784.275-18%-984088.175-22%-750192.483-41%-548347.775-57%
Usd Revenue--15806.80031200.050-49%157516.600-90%133304.245-88%99802.336-84%
Usd Total Gains Per Share--0.000-0.005+1858%0.008-103%0.000-221%0.001-126%
 EOD+3 -5MRQTTM+16 -17YOY+11 -225Y+10 -2310Y+10 -23

3.2. Fundamental Score

Let's check the fundamental score of Enorama Pharma AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.389
Price to Book Ratio (EOD)Between0-16.723
Net Profit Margin (MRQ)Greater than0-79.930
Operating Margin (MRQ)Greater than0-65.366
Quick Ratio (MRQ)Greater than10.849
Current Ratio (MRQ)Greater than11.269
Debt to Asset Ratio (MRQ)Less than10.432
Debt to Equity Ratio (MRQ)Less than10.760
Return on Equity (MRQ)Greater than0.15-0.704
Return on Assets (MRQ)Greater than0.05-0.400
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Enorama Pharma AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.490
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets34,385
Total Liabilities14,847
Total Stockholder Equity19,538
 As reported
Total Liabilities 14,847
Total Stockholder Equity+ 19,538
Total Assets = 34,385

Assets

Total Assets34,385
Total Current Assets12,964
Long-term Assets21,421
Total Current Assets
Cash And Cash Equivalents 6,153
Net Receivables 2,519
Inventory 4,292
Total Current Assets  (as reported)12,964
Total Current Assets  (calculated)12,964
+/-0
Long-term Assets
Property Plant Equipment 862
Long-term Assets Other 20,559
Long-term Assets  (as reported)21,421
Long-term Assets  (calculated)21,421
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,218
Long-term Liabilities4,629
Total Stockholder Equity19,538
Total Current Liabilities
Short-term Debt 133
Accounts payable 3,717
Other Current Liabilities 6,368
Total Current Liabilities  (as reported)10,218
Total Current Liabilities  (calculated)10,218
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)4,629
Long-term Liabilities  (calculated)0
+/- 4,629
Total Stockholder Equity
Common Stock6,394
Other Stockholders Equity 13,144
Total Stockholder Equity (as reported)19,538
Total Stockholder Equity (calculated)19,538
+/-0
Other
Cash and Short Term Investments 6,153
Common Stock Shares Outstanding 48,009
Liabilities and Stockholders Equity 34,385
Net Debt -5,717
Net Working Capital 2,746
Short Long Term Debt Total 436



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
> Total Assets 
0
0
0
9,168
6,186
19,279
16,243
13,626
12,150
17,423
14,823
15,487
20,254
23,278
19,266
38,830
27,153
28,043
34,025
42,585
36,030
37,892
37,670
40,905
48,442
42,707
42,022
50,933
43,165
53,823
42,351
48,721
35,960
33,380
37,261
34,385
34,38537,26133,38035,96048,72142,35153,82343,16550,93342,02242,70748,44240,90537,67037,89236,03042,58534,02528,04327,15338,83019,26623,27820,25415,48714,82317,42312,15013,62616,24319,2796,1869,168000
   > Total Current Assets 
0
0
0
1,091
524
11,214
6,676
3,973
1,913
4,842
1,846
2,100
3,596
6,077
882
18,279
4,715
5,527
11,566
18,016
10,509
12,415
11,877
12,823
19,640
13,644
12,640
22,409
15,528
27,070
16,494
11,752
11,877
10,187
14,961
12,964
12,96414,96110,18711,87711,75216,49427,07015,52822,40912,64013,64419,64012,82311,87712,41510,50918,01611,5665,5274,71518,2798826,0773,5962,1001,8464,8421,9133,9736,67611,2145241,091000
       Cash And Cash Equivalents 
0
0
0
841
439
10,487
6,567
3,828
1,666
4,507
1,648
165
1,575
4,009
566
16,430
3,604
2,007
7,943
14,605
3,871
1,807
3,034
4,734
9,299
2,101
3,977
12,200
6,711
15,816
3,718
4,139
2,389
247
6,741
6,153
6,1536,7412472,3894,1393,71815,8166,71112,2003,9772,1019,2994,7343,0341,8073,87114,6057,9432,0073,60416,4305664,0091,5751651,6484,5071,6663,8286,56710,487439841000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,325
6,780
5,989
8,095
7,677
4,787
7,055
3,071
4,471
7,410
4,322
4,913
5,155
2,588
2,519
2,5192,5885,1554,9134,3227,4104,4713,0717,0554,7877,6778,0955,9896,7809,325000000000000000000000
       Other Current Assets 
0
0
0
250
85
727
109
145
247
335
198
1,936
2,021
2,068
316
1,849
1,111
3,520
3,623
3,411
5,682
9,618
7,153
6,372
8,626
9,427
6,849
8,971
7,121
8,592
2,658
454
2,814
2,911
0
0
002,9112,8144542,6588,5927,1218,9716,8499,4278,6266,3727,1539,6185,6823,4113,6233,5201,1111,8493162,0682,0211,93619833524714510972785250000
   > Long-term Assets 
0
0
0
8,077
5,662
8,065
9,567
9,653
10,237
12,581
12,977
13,387
16,658
17,201
18,384
20,551
22,438
22,516
22,459
24,569
25,521
25,477
25,793
28,082
28,802
29,063
29,382
28,524
27,637
26,753
25,857
36,969
24,083
23,193
22,300
21,421
21,42122,30023,19324,08336,96925,85726,75327,63728,52429,38229,06328,80228,08225,79325,47725,52124,56922,45922,51622,43820,55118,38417,20116,65813,38712,97712,58110,2379,6539,5678,0655,6628,077000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
441
818
818
761
1,634
1,671
1,628
1,944
2,825
2,696
2,533
2,364
2,222
2,053
1,887
1,709
1,539
1,370
1,198
1,023
862
8621,0231,1981,3701,5391,7091,8872,0532,2222,3642,5332,6962,8251,9441,6281,6711,634761818818441000000000000000
       Intangible Assets 
0
0
0
0
0
8,065
9,567
9,653
10,237
12,581
12,977
13,387
16,658
17,201
18,384
20,110
21,620
21,698
21,698
22,934
23,850
23,849
23,849
25,257
26,106
26,530
27,018
26,302
25,584
24,866
24,148
23,430
22,713
21,995
21,277
0
021,27721,99522,71323,43024,14824,86625,58426,30227,01826,53026,10625,25723,84923,84923,85022,93421,69821,69821,62020,11018,38417,20116,65813,38712,97712,58110,2379,6539,5678,06500000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,849
23,849
25,257
26,106
26,530
27,018
26,302
25,584
24,866
24,148
12,000
22,713
21,995
0
0
0021,99522,71312,00024,14824,86625,58426,30227,01826,53026,10625,25723,84923,849000000000000000000000
> Total Liabilities 
0
0
0
2,644
2,376
7,170
5,251
4,546
4,654
11,792
11,353
8,126
15,917
22,088
17,460
21,811
14,691
19,723
19,451
35,405
33,445
37,173
36,806
39,128
45,445
39,752
39,443
29,579
32,790
54,487
51,698
17,197
14,369
20,654
17,570
14,847
14,84717,57020,65414,36917,19751,69854,48732,79029,57939,44339,75245,44539,12836,80637,17333,44535,40519,45119,72314,69121,81117,46022,08815,9178,12611,35311,7924,6544,5465,2517,1702,3762,644000
   > Total Current Liabilities 
0
0
0
2,094
1,901
3,770
1,851
1,146
1,254
8,542
8,353
5,076
4,917
7,038
5,960
14,711
9,391
10,623
10,351
10,405
10,245
13,973
15,189
18,612
25,431
20,806
21,016
11,678
15,412
37,631
35,031
12,426
9,621
15,929
12,869
10,218
10,21812,86915,9299,62112,42635,03137,63115,41211,67821,01620,80625,43118,61215,18913,97310,24510,40510,35110,6239,39114,7115,9607,0384,9175,0768,3538,5421,2541,1461,8513,7701,9012,094000
       Short-term Debt 
0
0
0
300
503
300
225
150
75
100
300
200
200
3,100
2,350
1,550
750
0
0
0
0
0
1,333
1,943
2,090
2,087
2,084
2,088
2,088
2,088
1,755
1,464
807
255
88
133
133882558071,4641,7552,0882,0882,0882,0842,0872,0901,9431,333000007501,5502,3503,10020020030010075150225300503300000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,333
1,943
2,090
2,087
2,084
2,088
2,088
2,088
1,755
1,464
807
255
88
0
0882558071,4641,7552,0882,0882,0882,0842,0872,0901,9431,3330000000000000000000000
       Accounts payable 
0
0
0
422
988
2,500
1,057
273
532
806
355
2,383
3,761
834
1,501
4,461
2,200
2,079
3,046
3,669
3,786
3,669
5,511
1,916
710
2,393
3,930
2,180
6,417
7,175
4,569
5,353
5,873
10,239
6,131
3,717
3,7176,13110,2395,8735,3534,5697,1756,4172,1803,9302,3937101,9165,5113,6693,7863,6693,0462,0792,2004,4611,5018343,7612,3833558065322731,0572,500988422000
       Other Current Liabilities 
0
0
0
1,372
410
970
569
723
647
7,636
7,698
2,493
956
3,104
2,109
8,700
6,441
8,544
7,305
6,736
6,459
10,304
8,345
14,753
22,631
16,326
14,674
7,410
6,907
28,368
28,707
5,609
2,941
2,827
487
6,368
6,3684872,8272,9415,60928,70728,3686,9077,41014,67416,32622,63114,7538,34510,3046,4596,7367,3058,5446,4418,7002,1093,1049562,4937,6987,6366477235699704101,372000
   > Long-term Liabilities 
0
0
0
550
475
3,400
3,400
3,400
3,400
3,250
3,000
3,050
11,000
15,050
11,500
7,100
5,300
9,100
9,100
25,000
23,200
23,200
21,617
20,516
20,014
18,946
18,427
17,901
17,378
16,856
16,667
4,771
4,748
4,725
4,701
4,629
4,6294,7014,7254,7484,77116,66716,85617,37817,90118,42718,94620,01420,51621,61723,20023,20025,0009,1009,1005,3007,10011,50015,05011,0003,0503,0003,2503,4003,4003,4003,400475550000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,667
3,766
3,264
2,746
2,227
1,701
1,178
656
467
445
422
0
0
0
0004224454676561,1781,7012,2272,7463,2643,7663,6670000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,200
17,950
16,750
16,750
16,200
16,200
16,200
16,200
16,200
16,200
4,326
4,326
4,326
0
0
004,3264,3264,32616,20016,20016,20016,20016,20016,20016,75016,75017,95023,200000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,849
23,849
25,257
26,106
26,530
27,018
26,302
25,584
24,866
24,148
23,430
22,713
21,995
0
0
0021,99522,71323,43024,14824,86625,58426,30227,01826,53026,10625,25723,84923,849000000000000000000000
> Total Stockholder Equity
0
0
0
6,524
3,810
12,109
10,992
9,080
7,496
5,631
3,470
7,361
4,337
1,190
1,806
17,019
12,462
8,320
14,574
7,180
2,585
719
864
1,777
2,997
2,955
2,579
21,354
10,375
-664
-9,347
31,524
21,591
12,726
19,691
19,538
19,53819,69112,72621,59131,524-9,347-66410,37521,3542,5792,9552,9971,7778647192,5857,18014,5748,32012,46217,0191,8061,1904,3377,3613,4705,6317,4969,08010,99212,1093,8106,524000
   Common Stock
0
0
0
575
575
709
709
709
709
709
709
753
753
753
753
828
828
828
864
864
864
864
864
923
923
965
965
1,201
1,201
1,201
1,201
4,039
4,039
4,039
5,769
6,394
6,3945,7694,0394,0394,0391,2011,2011,2011,201965965923923864864864864864828828828753753753753709709709709709709575575000
   Retained Earnings Total Equity000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,578
0
0
-180,824
0
0-180,824002,5780000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,995
20,209
0
0
0
0
0
0
0
0
0
0
0
0000000000020,20912,99500000000000000000000000
   Treasury Stock000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
6,605
5,949
14,463
14,463
14,250
14,833
6,919
7,314
14,718
17,989
11,539
16,722
36,370
37,879
16,036
33,959
31,195
32,111
18,187
23,187
32,590
40,653
13,435
99,782
126,446
126,446
-1,865
-10,548
173,972
176,550
176,550
194,746
13,144
13,144194,746176,550176,550173,972-10,548-1,865126,446126,44699,78213,43540,65332,59023,18718,18732,11131,19533,95916,03637,87936,37016,72211,53917,98914,7187,3146,91914,83314,25014,46314,4635,9496,605000



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,358
Cost of Revenue-43,196
Gross Profit-41,838-41,838
 
Operating Income (+$)
Gross Profit-41,838
Operating Expense-46,041
Operating Income-41,838-87,879
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense46,0410
 
Net Interest Income (+$)
Interest Income1,013
Interest Expense-3,589
Other Finance Cost-2,227
Net Interest Income-349
 
Pretax Income (+$)
Operating Income-41,838
Net Interest Income-349
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-44,613-39,063
EBIT - interestExpense = -45,427
-44,613
-41,024
Interest Expense3,589
Earnings Before Interest and Taxes (EBIT)-41,838-41,024
Earnings Before Interest and Taxes (EBITDA)-38,290
 
After tax Income (+$)
Income Before Tax-44,613
Tax Provision-0
Net Income From Continuing Ops-43,964-44,613
Net Income-44,613
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses43,196
Total Other Income/Expenses Net-2,775349
 

Technical Analysis of Enorama
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Enorama. The general trend of Enorama is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Enorama's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Enorama Pharma AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.5499531376731 < 7.72 < 10.30.

The bearish price targets are: 2.08 > 2.

Tweet this
Enorama Pharma AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Enorama Pharma AB. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Enorama Pharma AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Enorama Pharma AB.

Enorama Pharma AB Daily Moving Average Convergence/Divergence (MACD) ChartEnorama Pharma AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Enorama Pharma AB. The current adx is .

Enorama Pharma AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Enorama Pharma AB.

Enorama Pharma AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Enorama Pharma AB.

Enorama Pharma AB Daily Relative Strength Index (RSI) ChartEnorama Pharma AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Enorama Pharma AB.

Enorama Pharma AB Daily Stochastic Oscillator ChartEnorama Pharma AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Enorama Pharma AB.

Enorama Pharma AB Daily Commodity Channel Index (CCI) ChartEnorama Pharma AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Enorama Pharma AB.

Enorama Pharma AB Daily Chande Momentum Oscillator (CMO) ChartEnorama Pharma AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Enorama Pharma AB.

Enorama Pharma AB Daily Williams %R ChartEnorama Pharma AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Enorama Pharma AB.

Enorama Pharma AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Enorama Pharma AB.

Enorama Pharma AB Daily Average True Range (ATR) ChartEnorama Pharma AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Enorama Pharma AB.

Enorama Pharma AB Daily On-Balance Volume (OBV) ChartEnorama Pharma AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Enorama Pharma AB.

Enorama Pharma AB Daily Money Flow Index (MFI) ChartEnorama Pharma AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Enorama Pharma AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

Enorama Pharma AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Enorama Pharma AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.490
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Enorama with someone you think should read this too:
  • Are you bullish or bearish on Enorama? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Enorama? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Enorama Pharma AB

I send you an email if I find something interesting about Enorama Pharma AB.


Comments

How you think about this?

Leave a comment

Stay informed about Enorama Pharma AB.

Receive notifications about Enorama Pharma AB in your mailbox!